LETTER TO THE EDITOR
UK Haemophilia Centre Doctors’ Organisation guidance on the use of extended-half-life coagulation factor concentrates in routine clinical practice: Report of a meeting on their adoption by Belgian haemophilia treaters
Cedric Hermans,
Corresponding Author
Cedric Hermans
Division of Adult Haematology, Haemophilia Center, Saint-Luc University Hospital, Université catholique de Louvain, Brussels, Belgium
Correspondence: Cedric Hermans, Division of Adult Haematology, Haemophilia Centre, Saint-Luc University Hospital, 10 Avenue Hippocrate, 1200 Brussels, Belgium (
[email protected]).
Search for more papers by this author An Van Damme,
An Van Damme
Division of Paediatric Haematology, Haemophilia Center, Saint-Luc University Hospital, Université catholique de Louvain, Brussels, Belgium
Search for more papers by this author Gerry Dolan,
Gerry Dolan
St Thomas’ Hospital, London, UK
Search for more papers by this author Philip Maes,
Philip Maes
Antwerp University Hospital, Antwerp, Belgium
Search for more papers by this author Kathelijne Peerlinck,
Kathelijne Peerlinck
Division of Cardiovascular Disorders, Haemophilia Center, UZLeuven, Leuven, Belgium
Search for more papers by this author
Cedric Hermans,
Corresponding Author
Cedric Hermans
Division of Adult Haematology, Haemophilia Center, Saint-Luc University Hospital, Université catholique de Louvain, Brussels, Belgium
Correspondence: Cedric Hermans, Division of Adult Haematology, Haemophilia Centre, Saint-Luc University Hospital, 10 Avenue Hippocrate, 1200 Brussels, Belgium (
[email protected]).
Search for more papers by this author An Van Damme,
An Van Damme
Division of Paediatric Haematology, Haemophilia Center, Saint-Luc University Hospital, Université catholique de Louvain, Brussels, Belgium
Search for more papers by this author Gerry Dolan,
Gerry Dolan
St Thomas’ Hospital, London, UK
Search for more papers by this author Philip Maes,
Philip Maes
Antwerp University Hospital, Antwerp, Belgium
Search for more papers by this author Kathelijne Peerlinck,
Kathelijne Peerlinck
Division of Cardiovascular Disorders, Haemophilia Center, UZLeuven, Leuven, Belgium
Search for more papers by this author
First published: 04 September 2018
No abstract is available for this article.
REFERENCES
- 1Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016; 22: 487-498.
- 2Srivastava A, Brewer AK, Mauser-Bunschoten P, et al. Guidelines for the management of haemophilia. Haemophilia. 2013; 19: e1-e47.
- 3Collins PW. Personalized prophylaxis. Haemophilia. 2012; 18(Suppl. 4): 131-135.
- 4 EHC Newsletter (December 2016). Available at: https://www.ehc.eu/wp-content/uploads/EHC-December-Issue-WEB-1.pdf. (Accessed July 19, 2018).
- 5Feng D, Stafford KA, Broze GJ, Stafford DW. Evidence of clinically significant extravascular stores of factor IX. J Throm Haemost. 2013; 11: 2176-2178.
- 6Scott M, Nummi V, Lassila R, et al. Weekly recombinant FIX prophylaxis for severe haemophilia B in normal clinical practice: data from UKHCDO and Finland. Haemophilia. 2017; 23: e219-e249.
- 7Sommer JM, Buyue Y, Bardan S, et al. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thromb Haemost. 2014; 112: 932-940.
